SAN CARLOS, Calif. and
BRIDGEWATER, N.J., Oct. 2,
2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a
leader in synthetic biology, and Amneal Pharmaceuticals LLC, the
seventh largest generic drug manufacturer by volume in the U.S.,
today announced the formation of a second Exclusive Channel
Collaboration (ECC) for a target active pharmaceutical ingredient
(API). Utilizing Intrexon's robust microbial-based expression
system, the goal of the collaboration is to develop a consistent,
scalable, and cost-effective process for the targeted complex
API.
"The power of Intrexon's synthetic biology platform in
conjunction with our generic pharmaceutical development
capabilities is well-suited for the advance of novel approaches to
active pharmaceutical ingredients, enabling us to think beyond
current production platforms," said Chintu
Patel, CEO and Co-Chairman of Amneal. "The progress
achieved under our initial ECC led to this expansion of our
combined efforts."
This collaboration with Amneal marks Intrexon's third partnered
program this year in which the Company is applying its microbial
technology platform to produce APIs more efficiently than current
methods. By utilizing pathway development as well as strain
and fermentation optimization to advance API production processes,
Intrexon's approach replaces complex, multistep chemical synthesis
of APIs and also avoids resource-intensive isolation of
therapeutics from animals and plants.
"This expanded partnership leverages the strengths of both
organizations to develop and commercialize a high quality product
for patients through a more modernized and controlled manufacturing
process," said Gregory Frost, Ph.D.,
Senior Vice President and Head of Intrexon's Health Sector.
"We are pleased to collaborate with Amneal on this API in a profit
sharing structure given the value of this potential
opportunity."
Under the terms of the agreement, Amneal will have access to all
of Intrexon's technologies and expertise to improve production of
the target API. The agreement between Amneal and Intrexon
provides for a sharing in the research and development costs
associated with leveraging the value of their combined
capabilities, as well as a sharing of the operating profits.
About Amneal
Headquartered in Bridgewater, New Jersey, Amneal
Pharmaceuticals LLC is a U.S.-based developer and manufacturer of
high quality generic pharmaceuticals globally. The Company owns and
operates manufacturing, R&D, packaging, sales and distribution
facilities throughout the U.S. and abroad. Amneal prides itself on
an unwavering commitment to quality, reliability and innovative
approaches to maximizing value for all stakeholders. Amneal's
impressive growth has been spurred by extensive investment in
R&D, intelligent product selection, aggressive geographic
expansion, and a vertically integrated strategy. For more
information, visit www.amneal.com.
About Intrexon Corporation
Intrexon
Corporation (NYSE: XON) is a leader in synthetic biology
focused on collaborating with companies in Health, Food, Energy,
Environment, and Consumer Sectors to create biologically-based
products that improve the quality of life and the health of the
planet. Through the company's proprietary UltraVector®
platform and suite of technologies, Intrexon provides its partners
with industrial-scale design and development of complex biological
systems. The UltraVector® platform delivers unprecedented
control over the quality, function, and performance of living
cells. We call our synthetic biology approach and integrated
technologies Better DNA®, and we invite you to discover more at
www.DNA.com.
Trademarks
Intrexon, UltraVector, and Better DNA are
trademarks of Intrexon and/or its affiliates. Other names may
be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in
this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business. Although management believes that the plans and
objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release.
For more information contact:
Amneal Contact:
General Counsel
AMNEAL
PHARMACEUTICALS LLC
Bridgewater, New Jersey 08807, U.S.A.
Telefax: (908)
947-3147
Intrexon Corporation Contacts:
Corporate Contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com
Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
Investors@intrexon.com
SOURCE Intrexon Corporation